Xenetic Biosciences Inc Stock Price, News & Analysis

Xenetic Biosciences (NASDAQ: XBIO) announced approval for an exploratory study of its XCART platform to target Non-Hodgkin lymphoma (NHL) patients in Eastern Europe. The study aims to refine the process of neoantigen identification and CAR T candidate generation. Conducted at the Vitebsk Regional Clinical Oncological Center in Belarus, it will enroll adult B-Cell NHL patients, enabling further development of autologous CAR T-Cells. Collaborations with Scripps Research and PJSC Pharmsynthez are instrumental in advancing XCART technology, paving the way for future IND-enabling studies in the U.S.

Xenetic Biosciences (NASDAQ: XBIO) reported its 2020 financial results, highlighting advancements in its XCART™ platform aimed at targeting tumor-specific antigens, with a focus on B-cell lymphomas, representing a market opportunity exceeding $5 billion annually. The company reduced its R&D expenses to $1.7 million from $4.9 million in 2019. The net loss for 2020 was approximately $10.9 million, with cash reserves of $11.5 million. Recent partnerships aim to enhance XCART development, and the company anticipates key milestones including an exploratory study in Eastern Europe and regulatory meetings.

Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company, announced on March 3, 2021 that its CEO, Jeffrey Eisenberg, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing its XCART™ technology, designed to target specific neoantigens in tumors. A video presentation will be available on-demand starting March 9, 2021, at 7:00 AM ET. Xenetic is known for developing personalized CAR T therapies for B-cell lymphomas and utilizing its PolyXen® platform to enhance drug delivery.

Xenetic Biosciences (NASDAQ: XBIO) announced that its partner, PJSC Pharmsynthez, has filed a registration dossier for Epolong in Russia to treat anemia in chronic kidney disease patients. This follows positive Phase 3 clinical trial data demonstrating Epolong's efficacy. The collaboration utilizes Xenetic's PolyXen technology to enhance Epolong's pharmacological properties. If approved, Epolong would be the first product using PolyXen, with production expected to begin in Q1 2022. Pharmsynthez aims to complete registration by the end of 2021.

Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its CEO, Jeffrey Eisenberg, will present at NobleCon17 on January 19, 2021, at 9:45 AM ET. The virtual conference is free to attend and will feature a high-definition video webcast of the presentation.

The company focuses on advancing XCART, a personalized CAR T platform targeting tumor-specific neoantigens for treating B-cell lymphomas. Additionally, Xenetic utilizes its proprietary PolyXen drug delivery platform to enhance biologic drugs, in partnership with other biotech firms.

Xenetic Biosciences (NASDAQ:XBIO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. CEO Jeffrey Eisenberg will present during a fireside chat, with a video webcast available for on-demand viewing starting January 11 at 6:00 AM ET. The company focuses on advancing its XCART™ personalized CAR T platform targeting tumor-specific neoantigens, and it leverages its PolyXen® drug delivery platform for biotech partnerships.

Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced the closing of a registered direct offering on December 14, 2020, selling 2,448,980 shares at $2.45 each, generating approximately $6.0 million in gross proceeds. The funds will be allocated to general corporate purposes and the advancement of the proprietary XCART technology for treating B-cell Non-Hodgkin lymphomas. The offering was conducted under a shelf registration statement with H.C. Wainwright & Co. serving as the exclusive placement agent.

Xenetic Biosciences (NASDAQ: XBIO) announced a registered direct offering of 2,448,980 shares at $2.45 each, aiming for gross proceeds of approximately $6.0 million. The funds will support general corporate purposes and the advancement of the XCART platform, focusing on personalized CAR T therapies for B-cell Non-Hodgkin lymphomas. The offering is expected to close around December 14, 2020. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.

Xenetic Biosciences (NASDAQ: XBIO) announced positive results from a pivotal Phase 3 trial of Epolong, a polysialylated form of recombinant human erythropoietin. Conducted by partner Pharmsynthez, the study involved around 150 patients with chronic kidney disease. Epolong was shown to be non-inferior to Aranesp in effectiveness, with 74% of Epolong patients achieving hemoglobin targets compared to 52% for Aranesp. The results support the continued development of Epolong, which aims to reduce dosing frequency and side effects. Pharmsynthez plans to file for registration in Russia in 2021.